Weight-loss jabs could have surprise anti-cancer effect

New research suggests that weight loss injections, also known as GLP-1 receptor agonists, may have a significant anti-cancer effect beyond simply aiding in weight reduction.

- JANE KIRBY

While experts acknowledge the link between weight loss and reduced cancer risk, this study indicates the injections themselves may play a more direct role.

Researchers believe the anti-cancer properties may stem from the drugs’ ability to reduce inflammation, with newer GLP-1 receptor agonists potentially having the most pronounced effect. These medications work by suppressing appetite, making it easier for individuals to lose weight. They are available through the NHS for those with a high BMI and can also be obtained privately.

However, experts caution that further research is crucial to fully understand the relationship between weight loss injections and cancer prevention. Major names of GLP-1 receptor agonists, some of which are used to treat diabetes, include semaglutide (Wegovy and Ozempic), tirzepatide (Mounjaro), liraglutide (Saxenda) and exenatide (a drug which has now been discontinued).

The new research, published in the journal eClinicalMedicine, was presented at the European Congress on Obesity in Malaga. It found that first-generation GLP-1 receptor agonists such as liraglutide and exenatide may have anti-cancer benefits beyond weight loss.